A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy.
A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy.
复制标题
基于retrogen质粒的疫苗可产生针对自体癌症抗原生存素的高滴度抗体反应，并显示出抗肿瘤功效。
DOI：
10.1016/j.canlet.2005.05.035
复制
发表时间：
2006
期刊：
影响因子：
9.7
通讯作者：
Lin,AugustineY
中科院分区：
文献类型：
--
作者：
Decker,WilliamK;Qiu,Jianxia;Farhangfar,Farhang;Hester,JennyH;Altieri,DarioC;Lin,AugustineY
我们描述了使用逆转录酶质粒为基础的疫苗技术，打破耐受性，并产生一个强大的，剂量依赖性的抗体反应对自身癌抗原，生存素。我们进一步证明，这种现象是由于生存素抗原纳入retrogen系统，而不是一些独特的生存素。与设计用于产生抗体应答的其他遗传免疫方法相反，retrogen系统产生广泛的抗体同种型，指示Th-1和Th-2 CD 4+应答。Th-1应答的另外证据通过结肠癌转移的小鼠模型中的肿瘤生长抑制来证明。我们推测，这种具有成本效益的技术有一天可能会支持甚至取代单克隆抗体在靶向细胞表面癌抗原方面的应用。
We describe the use of retrogen plasmid-based vaccine technology to break tolerance and to generate a robust, dose-dependent antibody response against the self cancer antigen, survivin. We further demonstrate that this phenomenon is due to the incorporation of the survivin antigen into the retrogen system rather than to some peculiarity unique to survivin. In contrast to other genetic immunization methods designed to produce antibody responses, the retrogen system results in a broad range of antibody isotypes, indicative of both a Th-1 and a Th-2 CD4+response. Additional evidence of a Th-1 response is demonstrated by tumor growth inhibition in a mouse model of colon cancer metastasis. We speculate that this cost-effective technology could one day bolster or even supplant the use of monoclonal antibodies in the targeting of cell surface cancer antigens.